Aug. 24, 2015
On August 24, 2015 BioQuiddity Incorporated and Lee’s Pharmaceutical (HK) Limited announced the signing of a strategic license and supply agreement for the registration and commercialization of BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products in the PRC, Taiwan, Hong Kong, and Macau.
BioQuiddity’s unit-dose infusible pharmaceuticals are comprised of the pharmaceutical, delivery system and administration line in a self-contained, single use, ready-to-use presentation. The ropivacaine pharmaceutical is prefilled with 0.2% ropivacaine and is intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQuiddity’s propofol infusion pharmaceutical features both programmable flow and bolus capabilities.